Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets

Lung cancer is the leading cause of cancer-related deaths in the world. Immune checkpoint inhibitors (ICI) stimulate cytotoxic lymphocyte activity against tumour cells. These agents are available for the treatment of non-small cell lung cancer (NSCLC) after failure of platinum-based therapy. One rec...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:ESMO Open
Egile Nagusiak: Aguiar, Pedro Nazareth, De Mello, Ramon Andrade, Barreto, Carmelia Maria Noia, Perry, Luke Alastair, Penny-Dimri, Jahan, Tadokoro, Hakaru, Lopes, Gilberto de Lima
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2017
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5703392/
https://ncbi.nlm.nih.gov/pubmed/29209522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000200
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak